<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210226050506N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-06-09</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Chicory and Fumitory products on hot flashes</public_title>
      <acronym></acronym>
      <scientific_title>Effects of Chicory and Fumitory products on hot flashes in breast cancer patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54610</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study the restricted Randomization method of block randomization is used. Blocking is used to balance the number of samples assigned to each of the study groups.
Randomization method was performed using balanced block randomization and in the form of 4 blocks using computer. Each drug is labeled with a number from 1 to 64. Patients were divided into two groups for the trial: the first group (32 people) intervention group or drug group and the second control group (32 people) placebo group. Both groups were equally divided in terms of characteristics and coordinated conditions. The control group is assigned to "A" and the intervention group to "B", and then these two groups are divided into 6 blocks of 4: (1) AABB, (2) BBAA, (3) ABAB, (4) BABA, (5) AB BA, (6) BAAB .These blocks are randomly stacked together by a computer to form a chain of random groups (e.g. B B A A A A B B A B A B B A B A A B B A B A A B ) Patients then enter these groups in the order of enrollment.
For randomization, a randomization tool for random sequence software called Random allocation software is used. In addition to simple randomization, this software is also able to generate random sequences by block generation method. For concealment, we use allocation concealment, which is the method used to execute a random sequence on the study participants, so that the assigned group is not known before the individual is assigned. Drugs containing Chicory and Fumitory product or placebo were produced in the same shape and color and after coding were placed in sealed envelopes. Using opaque envelopes sealed with random sequences (Sequentially numbered, sealed, opaque envelopes) in which in this method each random sequence is recorded on a card and the cards are in the envelopes respectively. Are placed. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: In this study, both chicory and fumitory products and placebo are made by the pharmacist in the laboratory and dumped and coded in similar batteries that only the pharmacist knows about the codes and in the same way it will be given for researchers and basis on randomization finally for participants both so the researcher and the participant are blinded.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Breasts cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: Chicory and Fumitory products, obtained by at Institute of Medicinal Plants of shahid beheshti University, 5 ml per day until the end of the fourth weeks of intervention. In the preparation of this product, 20 grams of chicory seeds and 10 grams of aerial organs of  fumitory are boiled and smoothed with 150 ml of water. 70 ml of this extract is combined with 35 grams of sugar and 20 ml of vinegar. Intervention 2: Intervention group 2 : Placebo product, obtained by at Institute of Medicinal Plants of shahid beheshti University 5 ml per day until the end of intervention time. for produce this placebo, Oxymel syrup is used that combined with 1000 g  sugar and 500 ml water and 250ml vinegar  ,they are heated  To achieve the desired consistency, Then the natural color appropriate to the drug is added to it.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Publishing results in form of a PhD thesis and an article indexing in ISI

When:
After dissertation project thesis defence

To whom:
Public

Conditions:
For research reasons

Where to obtain:
Shahid Beheshti University of Medical Sciences

How to obtain:
Approving by responsible office

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nematollah Rostami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yadegare Imam Highway Saadat Abad St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1998734383</zip>
        <telephone>+98 21 2207 4087</telephone>
        <email>alireza.khosropanah1455@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nematollah Rostami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Yadgare Imam Highway .Saadat Abad St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1998734383</zip>
        <telephone>+98 21 2207 4087</telephone>
        <email>alireza.khosropanah1455@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women between 18 and 65 years
Breast cancer (stage 0-3)
Having at least two hot flashes in 24 hours
At least 4 weeks have elapsed since treatment with estrogen suppressive hormone therapy (Tamoxifen, LHRH agonists, Aromatase inhibitors)
Estrogen suppressive hormone therapy continued unchanged until the end of the intervention</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Lack of informed consent to the plan
Life expectancy is less than 6 months
Having another cancer at the same time as breast cancer
The patient is undergoing chemotherapy, radiotherapy or surgery
Use of acupuncture and complementary medicine (hypnosis, psychotherapy)
Taking antidepressants in the last 4 weeks
Use of Anxiolytic drug, Gabapentin, Pregabalin, Clonidine, Aspirin, Vitamin E, Omega 3, Phytoestrogenic supplements
Use of high phytoestrogenic diet
Allergy to distillated of Chicory and Fumitory
Kidney test (BUN,CR) is not in normal range
Laboratory range Liver enzymes AST and ALT are more than twice the normal range
Laboratory range and Total Bilirubin ≥2</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>CD50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Chicory and Fumitory products, obtained by at Institute of Medicinal Plants of shahid beheshti University, 5 ml per day until the end of the fourth weeks of intervention. In the preparation of this product, 20 grams of chicory seeds and 10 grams of aerial organs of  fumitory are boiled and smoothed with 150 ml of water. 70 ml of this extract is combined with 35 grams of sugar and 20 ml of vinegar.</i_keyword>
      <i_keyword>Intervention group 2 : Placebo product, obtained by at Institute of Medicinal Plants of shahid beheshti University 5 ml per day until the end of intervention time. for produce this placebo, Oxymel syrup is used that combined with 1000 g  sugar and 500 ml water and 250ml vinegar  ,they are heated  To achieve the desired consistency, Then the natural color appropriate to the drug is added to it.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Number of hot flashes: This variable registered by patient based on definied daily in hot flashes daily registration form. Timepoint: At a specific time of night, it is recorded daily and continuously for one week before the intervention and four weeks during the intervention with drug or placebo. Method of measurement: Number of hot flashes average of frequency during a week according to based on Daily Hot flashes Diary.</prim_outcome>
      <prim_outcome>The severity of hot flashes in four levels , mild , moderate, severe and very severe, is recorded according to the definition registered by the patient in the Daily hot flashes Diary. Timepoint: At a specific time of night, it is recorded daily and continuously for one week before the intervention and four weeks during the intervention with drug or placebo. Method of measurement: Based on the weekly average daily hot flashes intensity based on the Daily hot flashes Diary.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-12</approval_date>
        <contact_name>Name of ethics committee Ethic committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Velenjak st. Shahid Chamran Highway school of medicin 3th fioor Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
